- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 295 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Director Acquires Shares | 357 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Chief Development Officer and Director Acquires Shares | 384 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 18.03. | OKYO Pharma reports quality of life improvements in pain trial | 2 | Investing.com | ||
| 18.03. | OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain | 325 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 23.02. | OKYO Pharma LTD: OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress | 267 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.02. | Piper Sandler startet Coverage für OKYO Pharma mit 'Overweight'-Rating | 3 | Investing.com Deutsch | ||
| 20.02. | Piper Sandler initiates OKYO Pharma stock with Overweight rating | 2 | Investing.com | ||
| 13.02. | OKYO Pharma kündigt Aktienplatzierung im Wert von 20 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 13.02. | OKYO Pharma prices public offering at $1.85/share to raise up to $20M | 3 | Seeking Alpha | ||
| 13.02. | OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares | 460 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.02. | OKYO Pharma launches underwritten public offering of ordinary shares | 1 | Seeking Alpha | ||
| 12.02. | OKYO Pharma Announces Public Offering of Ordinary Shares | 369 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 11.02. | OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners | 583 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 10.02. | OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer | 313 | GlobeNewswire (Europe) | Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate, a blockbuster orphan therapy in corneal diseaseDr. Mantelli... ► Artikel lesen | |
| 10.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 30.01. | OKYO Pharma präsentiert Studienergebnisse zu Urcosimod auf jährlicher ASCRS-Tagung | 1 | Investing.com Deutsch | ||
| 30.01. | OKYO Pharma to present urcosimod NCP study results at ASCRS meeting | 1 | Investing.com |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 489,90 | +0,68 % | IDEXX Laboratories, Inc.: IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma | Helping clinicians investigate sooner and plan next steps with confidence IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the availability... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,240 | +1,31 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,040 | -0,95 % | BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting | PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient)... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,007 | -38,10 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,637 | -1,31 % | Anavex Life Sciences Corp.: Anavex Life Sciences Provides Comprehensive Regulatory Update | Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease Additional data submitted to the U.S. FDA with the objective... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,150 | +4,67 % | Precision BioSciences: Sind das jetzt Super-Schnäppchen? | Die Aktie von Precision BioSciences ist eines der wenigen Biotech-Papiere, die in diesem Jahr keinen Höhenflug erlebten. Im Gegenteil: Die Aktie hat ohne schlechte Unternehmensnews in den letzten Monaten... ► Artikel lesen | |
| CELLAVISION | 14,000 | 0,00 % | CellaVision: Solid Quarter driven by Strong Performance in Americas | Organic sales growth:Q4, 2025: 12.2% (-7.4)EBITDA margin:Q4, 2025: 33% (33)Oktober 1st - December 31st, 2025Net sales increased by 5.6% (-7.0) to SEK 197 m (187).Sales increased organically by 12.2%... ► Artikel lesen | |
| ZYMEWORKS | 22,200 | -0,89 % | Zymeworks Inc.: Zymeworks Appoints Kristin Stafford as Chief Financial Officer | VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse... ► Artikel lesen | |
| VTV THERAPEUTICS | 34,600 | -1,70 % | vTv Therapeutics Inc.: vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 4,860 | -0,41 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | - Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,420 | +1,14 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,170 | +2,63 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results | PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 0,915 | -1,08 % | MIRA PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| NUVATION BIO | 4,435 | 0,00 % | Nuvation Bio Acquires Japan Rights For Safusidenib; Now Owns Global Clinical Development Program | TOKYO (dpa-AFX) - Nuvation Bio (NUVB) announced it has amended existing exclusive license agreement for safusidenib with Daiichi Sankyo (4568.T) to include Japan rights. The agreement, as amended... ► Artikel lesen | |
| ONCONETIX | 1,530 | 0,00 % | Onconetix, Inc.: Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors | Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.